MophoSys - ExtraChancen

Inzwischen habe ich mich mit Ville7 abgemeldet (Mitgliedschaft beendet) und bin aber nun auf seiner persönlichen Agenda - da ich auch noch die Frechheit hatte mich über ihn zu beschweren.

Sein "offizieller" Sperrgrund bei elliv ist der Vorwurf bei WO mit mehreren Nicks aktiv zu sein. Dies stimmt nicht, ich hatte nur Ville7 und diese Mitgliedschaft ist seit gestern beendet, eine Sperre von elliv ist aus WO Sicht dennoch gerechtfertigt, da ich elliv nicht mit meinem korrekten Namen angemeldet habe (oops sorry Fehler ;) ). Daher habe ich jetzt auch diese Mitgliedschaft gekündigt.

Achja und mit Feststellung der IP ist es für ihn sicher ein leichtes eine Neuanmeldung von mir sofort wieder zu sperren und alle Postings zu löschen. Daher ist es auch sinnlos sich wieder anzumelden. Mal abgesehen von der mangelnden Lust wegen dem Kindergartenkrieg dort überhaupt noch zu posten.

Ich möchte nicht, dass auch ihr noch Probleme bekommt, daher bitte keine Verweise oder Links auf dieses Board, das ist schenbar ebenso unter sofortiger Sperrausführung. So hat er zahlreiche RMBS User gesperrt.

Jede Solidarisierung mit einer Meinung, die gegen die Ansicht des Mod ist kann zu einer Sperre führen. D.h. wenn ihr weiter posten wollt, dann seid vorsichtig in euren Aussagen zu diesem Thema, denn der hat echt was ander Waffel. :D

So- Thema ist für mich abgeschlossen. Es gibt ein Leben nach WO. Und hier kann ich ja posten wenn ich was zu sagen habe :)

----------

PS: Der 300er Zocker scheint derzeit eine Short Agenda zu haben ;)

Hugin-News: MorphoSys AG


MorphoSys erhält menschliche Zelllinie PER.C6® zur Produktion von Antikörpermaterial im Rahmen des MOR103-Programms

Corporate news- Mitteilung verarbeitet und übermittelt durch Hugin. Für den Inhalt der Mitteilung ist der Emittent verantwortlich. -------------------------------------------------- --------------

Die MorphoSys AG (Frankfurt: MOR; Prime Standard Segment, TecDAX) gab heute die Unterzeichnung eines zweiten PER.C6®-Lizenzvertrags mit dem holländischen Biotechnologie-Unternehmen Crucell N.V. (Euronext, NASDAQ: CRXL) und dessen Partner, dem Auftragsproduzenten DSM Biologics, bekannt. Der Vertrag ermöglicht MorphoSys den Einsatz der menschlichen Zelllinie PER.C6® zur Produktion von klinischem Antikörpermaterial im Rahmen des firmeneigenen Programms MOR103. Bei MOR103 handelt es sich um einen vollständig menschlichen HuCAL®-Antikörper, den MorphoSys im Bereich der entzündlichen Erkrankungen, beispielsweise zur Behandlung der Rheumatoiden Arthritis, entwickelt. Finanzielle Details wurden nicht bekannt gegeben. Darüber hinaus unterzeichnete MorphoSys einen Vertrag mit DSM Biologics zur Herstellung des klinischen Materials in deren FDA-geprüften Produktionsanlagen im niederländischen Groningen. "Die heutige Nachricht zeigt, dass MorphoSys bei der Entwicklung des MOR103-Programms auf Kurs ist, um den nächsten Entwicklungsschritt einzuleiten, die Einreichung alle notwendigen Anträge für den Start einer klinischen Phase-1-Studie in der zweiten Jahreshälfte 2007", erklärt Dr. Marlies Sproll, Vorstand für Forschung und Entwicklung bei MorphoSys. "Diese Zusammenarbeit kombiniert einen vollständig menschlichen Antikörper zur Behandlung von entzündlichen Erkrankungen mit einer ebenso vollständig menschlichen Produktionsmethode. Die Herstellung von menschlichen Antikörpern auf diese Art verspricht zahlreiche Vorteile gegenüber herkömmlichen Methoden, besonders für die Behandlung einer chronischen Krankheit wie der Rheumatoiden Arthritis." "Wir sind sehr erfreut, dass die Vorteile der PER.C6®-Zelllinie zur Antikörperproduktion einen anerkannten Antikörperspezialisten wie MorphoSys überzeugen konnten", kommentiert Dr. Jaap Goudsmit, Vorstand für Forschung und Entwicklung bei Crucell. "Wie wir es bei der Herstellung von Impfstoffen bereits gesehen haben, wird PER.C6® auch zur Produktion von Antikörpern zunehmend als Zellsystem akzeptiert." "Wir sind sehr erfreut, dass MorphoSys weiterhin erfolgreich die PER.C6®-Zelllinie einsetzt und sich für DSM Biologics als bevorzugten Auftragsproduzenten entschieden hat", fügt Terry Novak, Business Director und Chief Marketing Officer bei DSM Biologics, hinzu. "Zwei derart starke Technologie-Plattformen im Bereich der menschlichen Antikörper zu vereinen, ist besonders spannend." Für weitere Informationen kontaktieren Sie bitte: Dr. Claudia Gutjahr-Löser, Director Corporate Communications, Tel: +49 (0) 89 / 899 27-122, gutjahr-loeser@morphosys.com oder Mario Brkulj, Manager Public Relations, Tel: +49 (0) 89 / 899 27-454, brkulj@morphosys.com MorphoSys in Kürze: MorphoSys beschäftigt sich mit der Entwicklung und Anwendung von Technologien zur Herstellung synthetischer Antikörper, die die Entdeckung neuer Medikamente bzw. krankheitsassoziierter Zielmoleküle beschleunigen. Das Unternehmen wurde 1992 gegründet und verfügt über eine Reihe innovativer Technologien, allen voran HuCAL®, die Humane Kombinatorische Antikörper-Bibliothek, die weltweit von Wissenschaftlern zur Herstellung von menschlichen Antikörpern genutzt wird. Das Unternehmen hat Partnerschaften mit internationalen pharmazeutischen Unternehmen wie Bayer (USA), Boehringer Ingelheim (Deutschland), Bristol-Myers Squibb (USA), Centocor Inc. (USA), Daiichi Sankyo & Co., Ltd. (Japan), GPC Biotech AG (Deutschland), Hoffmann-La Roche AG (Schweiz), ImmunoGen Inc. (USA), Novartis AG (Schweiz), Merck & Co., Inc. (USA), Novoplant GmbH (Deutschland), OncoMed Pharmaceuticals Inc. (USA), Pfizer Inc. (USA), ProChon Biotech Ltd. (Israel), Schering AG (Deutschland), Schering-Plough (USA), Shionogi & Co., Ltd. (Japan), Xoma Ltd. (USA) und andere. MorphoSys ist im Markt der Forschungsantikörper durch seine Geschäftseinheit AbD Serotec tätig. Die Geschäftseinheit wurde im Jahr 2003 gegründet, um den nicht-therapeutischen Markt für MorphoSys zu erschließen. Die Aktivitäten in diesem Bereich wurden durch die Akquisition der Biogenesis-Gruppe in Großbritannien und in den USA im Januar 2005 sowie durch die Akquisition der Serotec-Gruppe in 2006 nachhaltig gestärkt. Weitere Informationen finden Sie unter www.morphosys.de/. About Crucell: Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a biotechnology company focused on research, development and worldwide marketing of vaccines and antibodies that prevent and treat infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell''s core portfolio includes a vaccine against hepatitis B and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine and the only aluminium-free hepatitis A vaccine on the market. The Company has a broad development pipeline, including both early-stage products and products almost ready to go to market. Several Crucell products are based on its unique PER.C6® production technology. The Company licenses this and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi aventis, GSK and Merck & Co. Crucell is headquartered in Leiden (the Netherlands), with subsidiaries in Switzerland, Spain, Italy and Korea. The Company employs about 900 people. For more information, please visit www.crucell.com. About DSM Biologics: DSM Biologics, a business unit of the DSM Pharmaceutical Products business group, is a leading contract manufacturer of biopharmaceutical products, the latest generation of drugs, mainly on the basis of native molecules and produced with the help of cell cultures. The company is renowned for its experience in the use of a broad range of cell culture systems (microbial and mammalian) and its expertise in the field of purification techniques. The company and Crucell have co-exclusive rights to license the high-producing PER.C6® human cell line to the pharmaceutical and biotechnology industry as a production platform for recombinant proteins and monoclonal antibodies. Established in 1986, DSM Biologics operates a manufacturing facility in Groningen, the Netherlands. About DSM: DSM is active worldwide in nutritional and pharma ingredients, performance materials and industrial chemicals. The company creates innovative products and services that help improve the quality of life. DSM''s products are used in a wide range of end markets and applications such as human and animal nutrition and health, cosmetics, pharmaceuticals, automotive and transport, coatings, housing and electrics & electronics (E&E). DSM''s strategy, named Vision 2010 - Building on Strengths, focuses on accelerating profitable and innovative growth of the company''s specialties portfolio. Market-driven growth, innovation and increased presence in emerging economies are key drivers of this strategy. The group has annual sales of approximately EUR 8 billion and employs around 23,000 people worldwide. DSM ranks among the global leaders in many of its fields. The company is headquartered in the Netherlands, with locations in Europe, Asia and the Americas. More information about DSM can be found at www.dsm.com. --- Ende der Mitteilung --- WKN: 663200; ISIN: DE0006632003; Index: CDAX, HDAX, Prime All Share, TECH All Share, TecDAX, MIDCAP; Notiert: Prime Standard in Frankfurter Wertpapierbörse, Geregelter Markt in Frankfurter Wertpapierbörse, Freiverkehr in Börse Berlin Bremen, Freiverkehr in Börse Düsseldorf, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Niedersächsische Börse zu Hannover, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Stuttgart;

sehr interessant.

urlcut.com/1cafu

----------------

Posted by: DewDiligence
In reply to: north40000 who wrote msg# 32962
          §Date:8/21/2006 2:15:54 AM
Post #of 32965

Immune System Might Be Revived to Fight AIDS, Cancer, HCV

[This research is relevant to a wide array of biotech companies, in particular MEDX.]

online.wsj.com/article/SB115611916112240632.html

>>
By MARK SCHOOFS
August 21, 2006

A spirited race between top immunology teams is set to culminate today with the publication of two scientific papers reaching broadly similar conclusions about the AIDS virus: It exploits the human body's natural mechanism for shutting down the immune system, and the process can be reversed.

The findings raise the tantalizing possibility that doctors one day could switch a patient's immune system back on, so that it could resume its fight against HIV, or even cancer cells, certain parasites or the virus that causes hepatitis C. Those very different diseases "have one common denominator," says Anthony Fauci, director of the National Institute for Allergy and Infectious Diseases. "They persist. They're chronic."

The studies, published in the journal Nature and its sister journal, Nature Medicine, build on almost 15 years of work by other researchers, including Kyoto University Prof. Tasuku Honjo, who in the early 1990s discovered a molecule, which he named PD-1, on the surface of disease-fighting T-cells. Subsequent research revealed that PD-1 is a natural regulator of the human immune system, acting like a brake on rampaging T-cells and potentially preventing them from attacking the body itself.

The latest findings are preliminary, and there isn't any way to predict whether this avenue of research will ever yield new treatments. And there's one more blazing caveat: Switching the immune system back on -- the most obvious treatment strategy -- might trigger autoimmune disease. Scientists currently studying PD-1 are sobered by the shocking experience of a German drug company's clinical trial conducted in London in March, in which six healthy volunteer patients received an experimental drug to stimulate the immune system and landed in intensive care, their lives in the balance, because the drug sent their immune systems into massive overdrive.

Nevertheless, research in this area is exploding. The Bill and Melinda Gates Foundation is funding a team researching how to turn the immune system back on in hepatitis C patients. Researchers at the National Institutes of Health are studying PD-1 in tuberculosis, one of the world's leading killers.

"This isn't just HIV," says Harvard University immunologist Bruce Walker, the lead researcher on the study published in Nature. "This is much broader."

Research has progressed furthest in cancer, where scientists have shown that PD-1 can shut down immune responses when it is activated by certain types of tumor cells. Last month, the U.S. Food and Drug Administration approved human testing of an experimental antibody designed to reverse the shutdown and permit the immune system to resume fighting cancer cells. The experimental drug is being developed by Medarex Inc., of Princeton, N.J., and Ono Pharmaceutical Co., of Japan.

When a virus or other pathogen enters the body, immune-system cells multiply furiously and send out potent chemicals, called cytokines, which cause inflammation. "When you get the flu, for example, you feel sick not so much because of the virus, but because of the immune system -- that's what gives you the aches and fevers," explains Drew Pardoll, an immunologist at Johns Hopkins University who has studied PD-1. Left unchecked, the raging immune response, including an excess of cytokines, could damage the body.

In a simple infection, such as the flu, the immune system apparently does its job and subsides. But if a pathogen isn't quickly cleared out, as in the case of chronic disease, then PD-1 goes to work and shuts down production of key types of immune-system cells. Much of this basic understanding was achieved only late last year in a study published in Nature and led by Emory University Prof. Rafi Ahmed and a student of his at the time, Daniel Barber.

The research being published today goes further to address one of the most vexing mysteries in the biology of AIDS. Key immune-system cells known as HIV-specific CD8 killer T-cells exist in high numbers in many HIV-infected patients. Early in the course of the infection, these cells kill other cells carrying the virus. But in long-term patients, these cells barely fight the virus at all. The reigning theory was that HIV somehow disabled them. That may still be true in part, but today's studies reveal that HIV actually exploits the body's own mechanism for shutting the cells down.

The PD-1 molecule buds on the surface of the killer T-cells that target HIV. By itself, PD-1 is inert and does nothing. But when PD-1 encounters a partner molecule, or ligand, the interaction sets off a chain reaction inside the killer T-cells. The T-cells multiply much more slowly or not at all, and overall they secrete far less of their powerful cytokines, the researchers found. Essentially, they abandon the fight.

The most dramatic finding is that the process can be reversed, at least in a test tube. When researchers added an antibody that blocked the interaction between PD-1 and its ligand, then the killer T-cells revived. They started multiplying again, and cytokine production increased. "I've never seen something as black and white," said Rafick Sékaly, a professor at Canada's Université de Montréal and a leader of the team whose study was published today in Nature Medicine.

The team, led by Harvard's Dr. Walker and researchers Cheryl Day and Daniel Kaufmann, made a further finding: Not only can PD-1 shut down the killer CD8 T-cells, but it also can affect command-and-control cells, known as CD4 cells. In other words, PD-1 acts on both the infantry and the generals. In one particularly striking bit of research, Dr. Kaufmann revived CD4 cells in five of six AIDS patients whose CD4 cells had shown zero activity against HIV.

Taken together, today's studies suggest that two critical types of immune system cells -- CD8 and CD4 -- can in most patients be rescued and remobilized to fight HIV.

The Walker and Sékaly research teams both are keen to test the hypothesis by giving patients an antibody that blocks the interaction between PD-1 and its ligand. The two researchers have initiated discussions with Medarex, developer of the experimental antibody about to be tested in cancer patients. Dr. Sékaly has even sent blood samples to Medarex so that it can run laboratory experiments on them.

In addition, Harvard University researcher Gordon Freeman has made his own antibodies to PD-1 and its ligands. He is busy planning tests of them in monkeys, with an eye to testing them in humans infected with HIV and hepatitis C.

Recently, Dr. Walker launched a new study of what he terms "elite controllers," the 0.33% of HIV patients who keep the virus in check for many years without drugs [#msg-12722870]. Dr. Walker believes that one reason these rare patients stay healthy may be that their immune cells lack PD-1, or that the interaction between PD-1 and its ligand might somehow be short-circuited. He has already begun to test these theories but doesn't yet have results.

A third scientific team, led by Richard Koup, chief of the immunology laboratory at the National Institutes of Health's Vaccine Research Center, also has been researching PD-1 in HIV. That study is scheduled to be published Sept. 5 in the online edition of the Journal of Experimental Medicine. Dr. Koup's team found that the interaction between PD-1 and its ligand appears to cause CD8 cells to die, not merely to stop functioning.
<<

21.08.2006 19:20
Dutton Associates Announces Investment Opinion: MorphoSys AG Strong Speculative Buy Rating in Update Coverage by Dutton Associates
Dutton Associates continues its coverage of MorphoSys (Nachrichten/Aktienkurs) AG (ADR OTC: MPSYY) (XETRA: MOR) reiterating a Strong Speculative Buy rating and an ADR $71.00 price target (EUR 56). The 9-page report by Dutton senior analyst Steve Handley is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Reuters, Knobias, and other leading financial portals.

MorphoSys AG, headquartered in Munich, Germany, is a leader in the development of human antibodies that generates approximately 50% of its revenues from the United States. Its technology -- known as HuCAL(R) (Human Combinatorial Antibody Library) -- facilitates the rapid and automated production of specific antibodies, and is gaining increased recognition by the pharmaceutical industry as an attractive and often preferred method for generating antibodies used in therapeutics. Concurrent with release of 2Q results, management updated its guidance for the full year -- increasing forecasted sales from EUR 50 million to up to EUR 52 million while reducing budgeted expenses by up to EUR 3 million. As a result, we have increased our estimated 2006 EPS to $1.58. These revisions reflect the previously announced expansion of the collaboration with Novartis (MorphoSys' leading client), a strong deal flow elsewhere, and the conclusions of an internal mid-year review of prior revenue and expense assumptions. The more optimistic outlook for near-term EPS is encouraging, but more relevant is the further substantiation of the Company's fundamentals by the proliferating agreements with pharmaceutical companies. MorphoSys clearly possesses proprietary technology that is very attractive to the pharmaceutical industry, and its partners can afford to compensate MorphoSys for its valuable expertise. Although the pattern of near term EPS is likely to remain uneven and difficult to predict, we believe that MorphoSys' long-term growth prospects are excellent, and we therefore continue to rate the stock a Strong Speculative Buy.

MorphoSys currently has collaborations with 12 of the world’s 20 largest pharmaceutical companies.

http://www.jmdutton.com/research/mor/reports/mor.de_report_082106.pdf

9Seiten pdf auf Englisch

Texte und Tabellen, Geschäftseinschätzungen usw.....

Table 2. Partnerships Among Top 20 Pharmaceutical Companies

Rank Company Initiated Current Collaboration

1 Pfizer 2003

2 Glaxo Smith Kline

3 Sanofi-Aventis

4 Johnson & Johnson (Centocor) 2001

5 Merck 2005

6 Astra Zeneca

7 Novartis 2004

8 Bristol-Myers Squibb 2001

9 Wyeth

10 Abbott Labs

11 Eli Lilly 2005

12 Hoffmann-LaRoche 2000

13 Amgen

14 Boehringer Ingelheim 2003

15 Takeda

16 Schering-Plough 2006

17 Astellas

18 Schering AG 2001

19 Bayer 1999

20 Daiichi Sankyo Co., Ltd. 2006

Source: MorphoSys AG